Find Voxelotor manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1446321-46-5, Oxbryta, Gbt440, Gbt 440, Gbt-440, Gtx-011
Molecular Formula
C19H19N3O3
Molecular Weight
337.4  g/mol
InChI Key
FWCVZAQENIZVMY-UHFFFAOYSA-N
FDA UNII
3ZO554A4Q8

Voxelotor
Voxelotor is an orally bioavailable modulator and stabilizer of sickle cell hemoglobin (HbS), with potential use in the treatment of sickle cell disease (SCD). Upon administration, voxelotor targets and covalently binds to the N-terminal valine of the alpha chain of HbS. This stabilizes HbS, thereby improving oxygen binding affinity. The binding of voxelotor to HbS prevents HbS polymerization, reduces sickling, decreases red blood cell (RBC) damage and increases the half-life of RBCs. This improves blood flow and decreases hemolytic anemia.
1 2D Structure

Voxelotor

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde
2.1.2 InChI
InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
2.1.3 InChI Key
FWCVZAQENIZVMY-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)N1C(=CC=N1)C2=C(C=CC=N2)COC3=CC=CC(=C3C=O)O
2.2 Other Identifiers
2.2.1 UNII
3ZO554A4Q8
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-3-pyridinyl)methoxy)benzaldehyde

2. Gbt440

3. Oxbryta

2.3.2 Depositor-Supplied Synonyms

1. 1446321-46-5

2. Oxbryta

3. Gbt440

4. Gbt 440

5. Gbt-440

6. Gtx-011

7. Hemoglobin Modulators-1

8. Voxelotor [usan]

9. 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

10. 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde

11. Chembl4101807

12. 3zo554a4q8

13. Voxelotor (usan)

14. 2-hydroxy-6-({2-[1-(propan-2-yl)-1h-pyrazol-5-yl]pyridin-3-yl}methoxy)benzaldehyde

15. Benzaldehyde, 2-hydroxy-6-((2-(1-(1-methylethyl)-1h-pyrazol-5-yl)-3-pyridinyl)methoxy)-

16. 2-hydroxy-6-((2-(1-(propan-2-yl)-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

17. Oxbryta (tn)

18. Voxelotor [inn]

19. Gbt-440(voxelotor)

20. Voxelotor [mi]

21. Voxelotor [who-dd]

22. Unii-3zo554a4q8

23. Voxelotor [orange Book]

24. Schembl15065529

25. Gtpl10559

26. Voxelotor(gbt440, Gtx011)

27. Dtxsid801027954

28. Bcp20182

29. Ex-a2980

30. Bdbm50235297

31. Zinc145969085

32. Ccg-267884

33. Cs-5317

34. Db14975

35. Sb19656

36. 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-3-pyridinyl)methoxy)benzaldehyde

37. Compound 36 [pmid: 28337324]

38. Ac-36867

39. As-57911

40. Da-44587

41. Hy-18681

42. Ft-0702904

43. S8540

44. D11330

45. Gbt-440;gbt440;voxelotor;gtx-011;gtx011;gtx 011

46. 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy) Benzaldehyde

2.4 Create Date
2013-07-15
3 Chemical and Physical Properties
Molecular Weight 337.4 g/mol
Molecular Formula C19H19N3O3
XLogP32.7
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass337.14264148 g/mol
Monoisotopic Mass337.14264148 g/mol
Topological Polar Surface Area77.2 Ų
Heavy Atom Count25
Formal Charge0
Complexity434
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Voxelotor is indicated to treat sickle cell disease in both adult and pediatric patients aged 4 years and older.


Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Voxelotor modifies hemoglobin to prevent painful and dangerous sickle cell crises that normally lead to organ damage, hospitalization, and sometimes death. It prevents low hemoglobin, which is normally associated with the destruction of sickled blood cells in sickle cell disease. Voxelotor has led to up to a 40% increase in hemoglobin in clinical trials.


5.2 MeSH Pharmacological Classification

Hematologic Agents

Drugs that act on blood and blood-forming organs and those that affect the hemostatic system. (See all compounds classified as Hematologic Agents.)


5.3 ATC Code

B06AX03


B - Blood and blood forming organs

B06 - Other hematological agents

B06A - Other hematological agents

B06AX - Other hematological agents

B06AX03 - Voxelotor


5.4 Absorption, Distribution and Excretion

Absorption

Voxelotor is rapidly absorbed after oral administration, with a plasma Tmax of 2 hours. Tmax in the red blood cells ranges from 17-24 hours. The Cmax, on average in whole blood and red blood cells occur 6 and 18 hours after an oral dose, respectively. Consumption of a high fat meal with voxelotor significantly increased exposure to the drug during clinical trials. After a daily dose of either 300, 600, or 900 mg for a period of 15 days, when steady-state concentrations were reached, the average RBC Cmax for the respective doses were measured to be 4950, 9610 and 14 000 g*h mL1, respectively.


Route of Elimination

62.6% of the voxelotor dose administered orally as well as its metabolites are found in the feces (with 33.3% as unchanged drug) and 35.5% in urine (with only 0.08% unchanged drug).


Volume of Distribution

The apparent volume of distribution of voxelotor in the central compartment is 338L and 72.2L in the plasma.


Clearance

The apparent oral clearance of voxelotor is approximately 6.7 L/h.


5.5 Metabolism/Metabolites

Voxeletor is heavily metabolized via 2 phases. Phase I consists of oxidation and reduction, while phase II consists of glucuronidation. Voseletor is oxidized mainly by CYP3A4, and to a lesser extent by CYP2C19, CYP2B6, and CYP2C9 hepatic cytochrome enzymes.


5.6 Biological Half-Life

The plasma elimination half-life of voxelotor in sickle cell disease patients is about 35.5 hours, according to the FDA label. The mean half-life in the red blood cell is 60 days. The average plasma half-life of voxelotor was 50 hours in patients with sickle cell disease, compared with 6185 hours in healthy patients, in one clinical study.


5.7 Mechanism of Action

Deoxygenated sickle hemoglobin (HbS) polymerization is the causal factor for sickle cell disease. The genetic mutation associated with this disease leads to the formation of abnormal, sickle shaped red blood cells that aggregate and block blood vessels throughout the body, causing vaso-occlusive crises. Voxelotor binds irreversibly with the Nterminal valine of the chain of hemoglobin, leading to an allosteric modification of Hb20, which increases the affinity for oxygen. Oxygenated HbS does not polymerize. By directly blocking HbS polymerization, voxelotor can successfully treat sickle cell disease by preventing the formation of abnormally shaped cells, which eventually cause lack of oxygenation and blood flow to organs.


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707244200,"product":"VOXELOTOR","address":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL","city":"HYDERABAD, AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"N\/A","customer":"N\/A","customerCountry":"SPAIN","quantity":"0.15","actualQuantity":"150","unit":"GMS","unitRateFc":"15000","totalValueFC":"2229","currency":"USD","unitRateINR":1233,"date":"07-Feb-2024","totalValueINR":"184950","totalValueInUsd":"2229","indian_port":"Hyderabad Air","hs_no":"29157090","bill_no":"7344510","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1679509800,"product":"VOXELOTOR DRUG SUBSTANCE (FREE OF CHARGE SAMPLE) (100% EOU)","address":"HOTEL DREAMZ PARK OFFICE COMPLEX\\r\\nUNIT G, 571\/2, ANNA SALAI,\\r\\nTEYNAMPET, CHENNAI, TAMIL NADU.","city":"CHENNAI,","supplier":"GLOBAL BLOOD THERAPEUTICS INC","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"PFIZER INC","customerCountry":"INDIA","quantity":"0.26","actualQuantity":"258.14","unit":"GMS","unitRateFc":"3.8","totalValueFC":"1012","currency":"USD","unitRateINR":"322.5","date":"23-Mar-2023","totalValueINR":"83238.26","totalValueInUsd":"1012","indian_port":"MADRAS AIR","hs_no":"29333990","bill_no":"5176006","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"HOTEL DREAMZ PARK OFFICE COMPLEX\\r\\nUNIT G, 571\/2, ANNA SALAI,\\r\\nTEYNAMPET, CHENNAI, TAMIL NADU."}]
23-Mar-2023
07-Feb-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty